UTHR Q4 2018 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$381M-17.9% YoY

Gross Profit

$350M91.6% margin

Operating Income

$132M34.5% margin

Net Income

$65M17.1% margin

EPS (Diluted)

$1.48

QoQ Revenue Growth

-7.6%

Cash Flow

Operating Cash Flow

$85M

Free Cash Flow

$34M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$612M

Stockholders' Equity

$2.8B

Cash & Equivalents

$669M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$381M	$465M	-17.9%
Gross Profit	$350M	$412M	-15.1%
Operating Income	$132M	$139M	-5.4%
Net Income	$65M	$19M	+243.7%

Revenue Segments

Remodulin

$159M58%

Orenitram

$50M18%

Adcirca

$42M15%

Unituxin

$24M9%

Geographic Segments

U

$351M92%

European Union And Others

$30M8%